The Efficacy and Safety of Pcsk9 Inhibitor in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-Label, Blinded End-Point Study with Vessel-Wall Mr Imaging (Topical-Mri), the Extended Year

Huang, Yen-Chu (PI)
Lee, Jiann-Der (CoPI)
Lee, Meng (CoPI)
Lin, Leng Chieh (CoPI)
Tsai, Yuan Hsiung (CoPI)
Yang, Jen-Tsung (CoPI)

Project: National Science and Technology Council › National Science and Technology Council Academic Grants

Abstract

ICAS之中風復發率高且易導致永久殘障，治療藥物主要是雙重抗血小板和高強度Statin，但Statin藥物的高副作用導致無法達成治療目標。PCSK9抑制劑為一新型藥物，合併Statin治療下，仍可有效降低低密度膽固醇而未增加副作用。本研究是使用高解析度MRI對ICAS的急性缺血性中風病人進行研究，評估PCSK9抑制劑的療效和安全性。目前全球試驗登錄資料中並無相關進行中的研究，未來值得進行phase3的試驗。此外，即將在台灣上市的Leqvio® (inclisiran) 為siRNA藥物可直接抑制PCSK9生成，一年只需要兩劑將大幅改善藥物遵從性，後續將規劃多中心試驗進一步研究長期治療的療效。

Project IDs

Project ID:PC11309-1665
External Project ID:NSTC113-2314-B182-061

Status	Active
Effective start/end date	01/08/24 → 31/07/25

Keywords

Intracranial atherosclerotic stenosis(ICAS)
alirocumab
PCSK9
MRI

Access Project

https://www.grb.gov.tw/search/planDetail?id=16928657

The Efficacy and Safety of Pcsk9 Inhibitor in Patients with Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-Label, Blinded End-Point Study with Vessel-Wall Mr Imaging (Topical-Mri), the Extended Year

Project Details

Abstract

Project IDs

Keywords

Access Project

Fingerprint